Screening for coronary heart disease: Has the time for universal imaging arrived?

Michael S. Lauer, MD
Director, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, National Institutes of Health; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 10122, Bethesda, MD 20892; e-mail: lauerm@nhlbi.nih.gov

Dr. Lauer receives support from the National Heart, Lung, and Blood Association (R01 HL-66004, R01 HL-072771, and P50 HL-77107, and K12 HD049091). He reports no personal financial relationships with any private commercial pharmaceutical, device, or imaging companies.

Michael S. Lauer, MD
Director, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, National Institutes of Health; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 10122, Bethesda, MD 20892; e-mail: lauerm@nhlbi.nih.gov

Dr. Lauer receives support from the National Heart, Lung, and Blood Association (R01 HL-66004, R01 HL-072771, and P50 HL-77107, and K12 HD049091). He reports no personal financial relationships with any private commercial pharmaceutical, device, or imaging companies.

Michael S. Lauer, MD
Director, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, National Institutes of Health; Contributing Editor, JAMA

Address: Michael S. Lauer, MD, Division of Prevention and Population Science, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 10122, Bethesda, MD 20892; e-mail: lauerm@nhlbi.nih.gov

Dr. Lauer receives support from the National Heart, Lung, and Blood Association (R01 HL-66004, R01 HL-072771, and P50 HL-77107, and K12 HD049091). He reports no personal financial relationships with any private commercial pharmaceutical, device, or imaging companies.